Toxicological assessment of a particulate yeast (1,3/1,6)-β-D-glucan in rats

被引:37
|
作者
Babicek, K.
Cechova, I.
Simon, R. R.
Harwood, M.
Cox, D. J.
机构
[1] BIOPHARM, Res Inst Biopharm & Vet Design, Jilove, Czech Republic
[2] Biothera Inc, Eagan, MN 55121 USA
关键词
(1,3)-beta-d-glucan; rat; toxicity; safety; yeast; NOAEL;
D O I
10.1016/j.fct.2007.03.013
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
This study investigates the toxicity of WGP((R)) 3-6, a yeast-derived P-glucan ingredient, during single-dose acute and sub-chronic toxicity studies in rats. For the acute study, Fisher-344 rats were administered WGPe 3-6 via gavage at a dose of 2000 mg/kg body weight, and any evidence of toxicity was monitored over a 14-day period. WGP((R)) 3-6 was well tolerated, indicating that the LD50 value is greater than 2000 mg/kg body weight. For the sub-chronic study, Fisher-344 rats (10/sex/group) were randomly allocated to receive daily gavage treatment with WGP((R)) 3-6 at doses of 0, 2,33.3, or 100 mg/kg body weight. Control and high-dose satellite recovery groups of each sex also were included. Full toxicological monitoring and endpoint investigations were performed throughout and upon completion of the study. No negative effects on animal weights or food consumption attributable to WGP((R)) 3-6 were evident at any dose. In addition, no mortality, clinical pathology, functional/behavioral, microscopic, or gross observations indicating toxicity were observed. Sporadic changes in some biochemical and hematological parameters were observed; however, since the effects were within the physiological ranges in historical controls, were not dose-responsive, or were not observed in both sexes, they were determined to be of no toxicological significance. In conclusion, no adverse or toxic effects were observed after subchronic oral administration of 2, 33.3, or 100 mg/kg body weight/day of WGP((R)) 3-6 in Fisher-344 rats, and therefore, a no observed adverse effect level (NOAEL) of 100 mg/kg body weight/day, the highest dose tested, was determined. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1719 / 1730
页数:12
相关论文
共 50 条
  • [21] The effect of molecular weight and β-1,6-linkages on priming of macrophage function in mice by (1,3)-β-D-glucan
    Cleary, JA
    Kelly, GE
    Husband, AJ
    IMMUNOLOGY AND CELL BIOLOGY, 1999, 77 (05): : 395 - 403
  • [22] Intestinal and Systemic Immune Development and Response to Vaccination Are Unaffected by Dietary (1,3/1,6)-β-D-Glucan Supplementation in Neonatal Piglets
    Hester, Shelly N.
    Comstock, Sarah S.
    Thorum, Shannon C.
    Monaco, Marcia H.
    Pence, Brandt D.
    Woods, Jeffrey A.
    Donovan, Sharon M.
    CLINICAL AND VACCINE IMMUNOLOGY, 2012, 19 (09) : 1499 - 1508
  • [23] No interference of the 1,3-β-D-glucan containing nutritional supplement ImunixX with the 1,3-β-D-glucan serum test
    Spriet, Isabel
    Desmet, Stephanie
    Willems, Ludo
    Lagrou, Katrien
    MYCOSES, 2011, 54 (05) : E352 - E353
  • [24] Effects of β-(1,3-1,6)-D-glucan on irritable bowel syndrome-related colonic hypersensitivity
    Asano, Teita
    Tanaka, Ken-ichiro
    Suemasu, Shintaro
    Ishihara, Tomoaki
    Tahara, Kayoko
    Suzuki, Toshio
    Suzuki, Hidekazu
    Fukudo, Shin
    Mizushima, Tohru
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2012, 420 (02) : 444 - 449
  • [25] Water Solubilization of Fullerene Derivatives by β-(1,3-1,6)-D-Glucan and Their Photodynamic Activities toward Macrophages
    Ikeda, Atsushi
    Iizuka, Tatsuya
    Maekubo, Naotake
    Nobusawa, Kazuyuki
    Sugikawa, Kouta
    Koumoto, Kazuya
    Suzuki, Toshio
    Nagasaki, Takeshi
    Akiyama, Motofusa
    CHEMISTRY-AN ASIAN JOURNAL, 2017, 12 (10) : 1069 - 1074
  • [26] Efficacy of Intraperitoneally and Orally Administered ProVale, a Yeast β-(1,3)/(1,6)-D-glucan Product, in Inhibiting Xenoma Formation by the Microsporidian Loma salmonae on Rainbow Trout Gills
    Guselle, Nicole J.
    Speare, David J.
    Markham, R. J. Fred
    Patelakis, Shane
    NORTH AMERICAN JOURNAL OF AQUACULTURE, 2010, 72 (01) : 65 - 72
  • [27] Serum (1,3)-β-D-Glucan for Screening of Neonatal Fungemia
    Kamirul Islam
    Nazima Khatun
    Ujjal Mondal
    Kuntalkanti Das
    Kaustav Nayek
    Indian Pediatrics, 2022, 59 : 499 - 500
  • [28] Serum (1,3)-β-D-Glucan for Screening of Neonatal Fungemia
    Islam, Kamirul
    Khatun, Nazima
    Mondal, Ujjal
    Das, Kuntalkanti
    Nayek, Kaustav
    INDIAN PEDIATRICS, 2022, 59 (06) : 499 - 500
  • [29] 1,3-β-D-glucan in cryptococcal meningitis
    Rhein, Joshua
    Boulware, David R.
    Bahr, Nathan C.
    LANCET INFECTIOUS DISEASES, 2015, 15 (10): : 1136 - 1137
  • [30] A phase I/II trial of beta-(1,3)/(1,6) D-glucan in the treatment of patients with advanced malignancies receiving chemotherapy
    Weitberg, Alan B.
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2008, 27 (1)